Education
About Us
Working with TipRanks
Follow Us
Restart Life Sciences (TSE:HEAL)
:HEAL
Top Page
Restart Life Sciences
(HEAL)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.11
▼(-2.73% Downside)
The score is primarily held down by very weak financial performance (pre-revenue, persistent losses/cash burn, and negative equity). Technical indicators are only moderately supportive and largely neutral, while valuation metrics provide limited support due to the negative P/E and no dividend.
Restart Life Sciences (HEAL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$4.02M
Dividend YieldN/A
Average Volume (3M)3.65K
Price to Earnings (P/E)―
Beta (1Y)2.25
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding36,550,354
10 Day Avg. Volume5,146
30 Day Avg. Volume3,650
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-3.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Restart Life Sciences Business Overview & Revenue Model
Company DescriptionRestart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
How the Company Makes Money
Restart Life Sciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.47K |
| Gross Profit | 0.00 | 0.00 | 25.41K | -3.79K | -5.00K | 1.73K |
| EBITDA | -1.27M | -656.20K | -1.20M | -1.84M | -2.68M | -25.23M |
| Net Income | -562.53K | 224.75K | -1.22M | -3.76M | -2.68M | -25.23M |
Balance Sheet | ||||||
| Total Assets | 277.56K | 190.40K | 31.06K | 296.79K | 881.16K | 3.05M |
| Cash, Cash Equivalents and Short-Term Investments | 262.38K | 169.95K | 8.09K | 266.52K | 218.73K | 2.14M |
| Total Debt | 0.00 | 79.88K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 214.89K | 489.47K | 841.66K | 255.44K | 422.06K | 382.96K |
| Stockholders Equity | 62.67K | -299.07K | -810.60K | 41.34K | 459.10K | 2.66M |
Cash Flow | ||||||
| Free Cash Flow | -328.58K | -71.77K | -277.53K | -1.44M | -1.95M | -422.11K |
| Operating Cash Flow | -328.58K | -71.77K | -277.53K | -1.44M | -1.95M | -856.53K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 29.64K | 2.90M |
| Financing Cash Flow | 481.95K | 75.00K | 19.10K | 1.49M | 0.00 | 0.00 |
Restart Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
TSE:HEAL
Restart Life Sciences
0.11
0.07
175.00%
TSE:CYBN
Cybin
0.14
0.00
0.00%
TSE:ENBI
Entheon Biomedical
0.10
-0.17
-62.96%
TSE:MYND
MYND Life Sciences
0.07
-0.03
-30.00%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.01
-50.00%
TSE:MBIO
Mindbio Therapeutics Corp.
1.10
-6.90
-86.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.